The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 2, 2006, Pages 365-382

  Crane, Christopher H ^a   Varadhachary, Gauri ^a   Wolf, Robert A ^a   Pisters, Peter W T ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Borderline resectable; Chemotherapy; Molecular targeted therapy; Neoadjuvant; Pancreatic cancer; Pre operative; Radiotherapy; Resectable

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ANASTOMOSIS LEAKAGE; ARTICLE; BILE DUCT OBSTRUCTION; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; DEHYDRATION; DIAGNOSTIC ACCURACY; DRUG DOSE REGIMEN; DRUG TARGETING; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; METASTASIS POTENTIAL; MULTIDETECTOR COMPUTED TOMOGRAPHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREATICODUODENECTOMY; PANCREATOGRAPHY; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RADIATION INJURY; RECTUM CANCER; RECURRENCE RISK; TREATMENT OUTCOME; VALIDATION PROCESS; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY DOSAGE;

EID: 33645016483     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2005.11.005     Document Type: Article

References (60)

1. Exocrine pancreas F.L. Greene D.L. Page I.D. Fleming et. al. AJCC Cancer Staging Manual 6th edn 2002 Springer New York 157-164
2. J.F.R.C. Tseng J.E. Lee P.W. Pisters et. al. Pancreaticoduodenectomy with vascular resection: Margin status and survival duration J Gastrointest Surg 8 2004 935-949
3. J.S. Macdonald S.R. Smalley J. Benedetti et. al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725-730
4. J.E. Krook C.G. Moertel L.L. Gunderson et. al. Effective surgical adjuvant therapy for high-risk rectal carcinoma N Engl J Med 324 1991 709-715
5. Anonymous Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group Cancer 59 1987 2006-2010
6. E. Kapiteijn C.A. Marijnen I.D. Nagtegaal et. al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638-646
7. T.M. Breslin K.R. Hess D.B. Harbison et. al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration Ann Surg 8 2001 123-132
8. T.A. Sohn C.J. Yeo J.L. Cameron et. al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567-579
9. J.E. Lim M.W. Chien C.C. Earle Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients Ann Surg 237 2003 74-85
10. J.H. Klinkenbijl J. Jeekel T. Sahmoud et. al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776-782
11. J.P. Neoptolemos D.D. Stocken H. Friess et. al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200-1210
12. R. Sauer H. Becker W. Hohenberger et. al. Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731-1740
13. C.P. Raut D.B. Evans C.H. Crane et. al. Neoadjuvant therapy for resectable pancreatic cancer Surg Oncol Clin N Am 4 2004 639-661
14. P.W.T. Pisters R.A. Wolff N.A. Janjan et. al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome J Clin Oncol 20 2002 2537-2544
15. T.M. Breslin K.R. Hess D.B. Harbison et. al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration Ann Surg Oncol 8 2001 123-132
16. P.W. Pisters J.L. Abbruzzese N.A. Janjan et. al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma J Clin Oncol 16 1998 3843-3850
17. A.M. Lowy J.E. Lee P.W. Pisters et. al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease Ann Surg 226 1997 632-641
18. T.A. Sohn C.J. Yeo J.L. Cameron et. al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567-579
19. P.W. Pisters R.A. Wolff C.H. Crane et. al. Combined-modality treatment for operable pancreatic adenocarcinoma Oncology 19 2005 393-404
20. P.W.T. Pisters J.L. Abbruzzese N.A. Janjan et. al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma J Clin Oncol 16 1998 3843-3850
21. D.B. Evans T.A. Rich D.R. Byrd et. al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 1992 1335-1339
22. R.A. Wolff D.B. Evans C.H. Crane et. al. Initial results of a preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma Proc Am Soc Clin Oncol 21 2002 130a [Abstract]
23. R.A. Wolff D.B. Evans D.M. Gravel et. al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma Clin Cancer Res 7 2001 2246-2253
24. T.A. Rich N.A. Janjan J.L. Abbruzzese et. al. (Response) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 15 1997 3292-3293
25. P.W.T. Pisters W.A. Hudec K.R. Hess et. al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients Ann Surg 234 2001 47-55
26. P.W.T. Pisters W.A. Hudec J.E. Lee et. al. Preoperative chemoradiation for patients with pancreatic cancer: Toxicity of endobiliary stents J Clin Oncol 18 2000 860-867
27. D.O. Faigel G.G. Ginsberg J.S. Bentz et. al. Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions J Clin Oncol 15 1997 1439-1443
28. J. Suits R. Frazee R.A. Erickson Endoscopic ultrasound and fine needle aspiration for the valuation of pancreatic masses Arch Surg 134 1999 639-643
29. J. Hoffman S. Lipsitz T. Pisansky et. al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An eastern cooperative oncology group study J Clin Oncol 16 1998 317-323
30. S.P. Povoski M.S. Karpeh K.C. Conlon et. al. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy Ann Surg 230 2 1999 131-142
31. Mullen JT, Lee JH, Gomez HF et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg; in press.
32. J.M. Pipas S.E. Mitchell R.J. Barth et. al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 50 2001 1317-1322
33. C.J. McGinn M.M. Zalupski I. Shureiqi et. al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 19 2001 4202-4208
34. A.W. Blackstock S.A. Bernard F. Richards et. al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer J Clin Oncol 17 1999 2208-2212
35. C.H. Crane R.A. Wolff J.L. Abbruzzese et. al. Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index Semin Oncol 28 2001 25-33
36. C.-P. Li Y. Chao K.-H. Chi et. al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study Int J Radiat Oncol Biol Phys 57 2003 98-104
37. A. Blackstock M. Tempero D. Niedwiecki et. al. Cancer and leukemia group b (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with localoregional adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 51 2001 31 [abst #49]
38. C.J. McGinn M.M. Zalupski I. Shureiqi et. al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 19 2001 4202-4228
39. McGinn C, Talamonti M, Small W, et al. A phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer. Proc 2004 ASCO GI Symposium, San Francisco, Ca:PG 89, Abstract #96, 2004.
40. H.A. Burris III M.J. Moore J. Andersen et. al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403-2413
41. C.H. Crane J.L. Abbruzzese D.B. Evans et. al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52 2002 1293-1302
42. J. Cassidy W. Scheithauer J. McKendrick et. al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial J Clin Oncol 2004 [Abstract 3509]
43. T.H. Cartwright A. Cohn J.A. Varkey et. al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 2002 160-164
44. J. Dunst T. Reese T. Sutter et. al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer J Clin Oncol 20 2002 3983-3991
45. C. Crane L. Ellis J. Abbruzzese et. al. Phase I trial of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenocarcinoma Proc Am Soc Clin Oncol 23 2005 16S-316s
46. D.H. Gorski M.A. Beckett N.T. Jaskowiak et. al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374-3378
47. J. Wey F. Fan M. Gray et. al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines Cancer 104 2005 427-438
48. R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58-62
49. C.G. Willett Y. Boucher E. di Tomaso et. al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145-147
50. Bonner J, Guralt J, Harari PM et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. ASCO 2004 Annual Meeting: Abstract #5507, 2004.
51. E.P. Tamm P.M. Silverman C. Charnsangavej et. al. Diagnosis, staging, and surveillance of pancreatic cancer AJR Am J Roentgenol 180 2003 1311-1323
52. J.C. Cusack G.M. Fuhrman J.E. Lee et. al. Management of unsuspected tumor invasion of the superior mesenteric-portal venous confluence at the time of pancreaticoduodenectomy Am J Surg 168 1994 352-354
53. J.M. Jessup G. Steele Jr R.J. Mayer et. al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma Arch Surg 128 1993 559-564
54. J. Jeekel A.D. Treurniet-Donker Treatment perspectives in locally advanced unresectable pancreatic cancer Br J Surg 78 1991 1332-1334
55. R. White C. Lee M. Anscher et. al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas Ann Surg Oncol 6 1999 38-45
56. K.E. Todd B. Gloor J.S. Lane et. al. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole J Gastrointest Surg 2 1998 159-166
57. E. Bajetta M. Di Bartolomeo S.C. Stani et. al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: Results of a feasibility study Int J Radiat Oncol Biol Phys 45 1999 285-289
58. G.V. Kornek A. Schratter-Sehn A. Marczell et. al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin Br J Cancer 82 2000 98-103
59. Varadhachary G, Tamm E, Abbruzzese J, et al., Borderline resectable pancreatic cancer: Definitions, management, and the role of preoperative therapy. Ann Surg; in press.
60. V.K. Mehta G. Fisher J.A. Ford et. al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas J Gastrointest Surg 5 2001 27-35